Grifols SA - ADR - Level III (GRFS) Company Profile & Statistics

Grifols SA - ADR - Level III
GRFS
(Nasdaq - US)
N/A
6.32
+0.05 (+0.80%)
in:usd•As of: Apr 26, 2024 09:32 UTC -4
Open
6.33
High
6.33
Low
6.32

About Grifols SA - ADR - Level III

CEO

V¿ctor Grifols Deu

Headquarters

152 parc de negocis can sant joan , sant cugat del vall¿s

barcelona, u3 08174, spain

Auditor

KPMG Auditores, S.L.

Employees

23,234

Share Holders

N/A

Website

www.grifols.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain.

Grifols SA - ADR - Level III Statistics

Valuation Measures

Market Capitalization ²	N/A
Enterprise Value	N/A
Enterprise Value/EBITDA (ttm)	N/A
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	0.51
Price to Sales (ttm)	N/A
Price to Cash (ytd)	8.10

Profitability

Gross Margin (ttm)	18.17%
Operating Margin (ttm)	2.16%
Profit Margin (ttm)	-0.95%
Return on Equity (ttm)	1.73%
Return on Invested Capital (ttm)	0.04%
Return on Assets (ttm)	0.66%

Income Statement

Revenue (ttm)	5.11B
Revenue Per Share (ttm)	7.43
Gross Profit (ttm)	1.93B
EBITDA (ttm)³	566.64M
Net Income Avi to Common (ttm)	5.42M
Diluted EPS (ttm)	N/A

Share Statistics

Beta (5Y Monthly)	0.56
52-Week Change	-12.22%
S&P500 52-Week Change	24.47%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	N/A
Dividend Yield	0.00%
Float ⁴	0.00
% Held by Insiders	0.19%
% Held by Institutions	0.00%

Balance Sheet

Total Cash (mrq)	N/A
Total Cash Per Share (mrq)	N/A
Total Debt (mrq)	N/A
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	N/A
Quick Ratio (mrq)	1.32%
Book Value Per Share (mrq)	N/A

Cash Flow

Operating Cash Flow Per Share (ytd)	N/A
Free Cash Flow (ytd)	0.00

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Grifols SA - ADR - Level III

Trade With A Regulated Broker